This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
GLP-1 medications are widely used to treat type 2 diabetes and help some people manage their weight. These medications can reduce appetite and help people feel full sooner. Early research also suggests they may help reduce binge-eating episodes for some people.
But those same effects can be concerning for people with eating disorders or a history of eating disorders. Because these medications can change how people eat and how much weight they lose, clinicians need to carefully consider whether they are appropriate for each patient.
A new study published in World Psychiatry offers guidance to help clinicians make those decisions. Tanya M. Halliday, Ph.D., R.D., associate professor in the Department of Nutrition and Integrative Physiology, co-authored the study with an international group of experts, researchers and people with lived experience.
The research team gathered a panel of 45 experts and people with lived experience. Over three rounds of feedback, the group worked toward agreement on recommendations for using GLP-1 medications safely in people with eating disorders.
The group recommended that clinicians screen patients for current or past eating disorders before prescribing a GLP-1 medication. They also recommended regular check-ins during treatment to watch for signs that eating disorder symptoms are developing or getting worse. How often patients are monitored should depend on their individual level of risk.
The guidance also calls for clear educational materials for patients and health care providers.
Source link







